9 active trials 3 recruiting 4 Phase 3 8 disease areas
| Phase 1 | 1 | |
| Phase 1/2 | 1 | |
| Phase 2 | 3 | |
| Phase 3 | 4 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Glioma | Recruiting | 2026-08-28 |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC… | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-05-19 |
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally… | Non Small Cell Lung Cancer | Recruiting | 2026-04-13 |
| NCT07712757 | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma | Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation | Not Yet Recruiting | 2026-07-17 |
| Phase 2 | ||||
| NCT07703436 | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who… | Grade 2 IDH1-mutant Glioma | Not Yet Recruiting | 2026-09-22 |
| NCT04395677 | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | Non Small Cell Lung Cancer | Active, Not Recruiting | 2026-02-06 |
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | Non Small Cell Lung Cancer | Active, Not Recruiting | 2026-01-07 |
| Phase 1/2 | ||||
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Advanced Solid Tumor | Active, Not Recruiting | 2026-01-14 |
| Phase 1 | ||||
| NCT07742384 | Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib | Healthy Adult Participants | Not Yet Recruiting | 2026-08-03 |
Lung Cancer (4) · Non-Small Cell Lung Cancer (NSCLC) (4) · Glioma (3) · Breast Cancer (1) · Glioblastoma (1) · Ovarian Cancer (1) · Pancreatic Cancer (1) · Prostate Cancer (1)